Association between serum homocysteine concentration with coronary artery disease in Iranian patients

ARYA Atherosclerosis

Volumn 7, Issue 2, 2011, Pages 63-67

  Mirdamadi, Ahmad ^a   Farzamnia, Hamid ^b   Varzandeh, Pooyan ^a   Almasi, Naser ^c   Arasteh, Mahfar ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Coronary artery disease; Homocysteine

Indexed keywords

EID: 84858133085     PISSN: 17353955     EISSN: 22516638     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Smith SC. Current and future directions of cardiovascular risk prediction. Am J Cardiol 2006; 97(2A): 28A-32A.
2. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 2007; 219: 187-203.
3. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit 2002; 8(1): RA5-12.
4. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114(5): 473-501.
5. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses 2004; 62(4): 499-506.
6. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325(7374): 1202.
7. Taylor LM, Jr., Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 1999; 29(1): 8-19.
8. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277(22): 1775-81.
9. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324(17): 1149-55.
10. Genest JJ, McNamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990; 16(5): 1114-9.
11. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92(10): 2825-30.
12. Sadeghian S, Fallahi F, Salarifar M, Davoodi G, Mahmoodian M, Fallah N, et al. Homocysteine, vitamin B12 and folate levels in premature coronary artery disease. BMC Cardiovasc Disord 2006; 6: 38.
13. Ceperkovic Z. The role of increased levels of homocysteine in the development of cardiovascular diseases. Med Pregl 2006; 59(3-4): 143-7.
14. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337(4): 230-6.
15. Onat A, Hergenc G, Kucukdurmaz Z, Can G, Ayhan E, Bulur S. Serum folate is associated with coronary heart disease independently of homocysteine in Turkish men. Clin Nutr 2008; 27(5): 732-9.
16. Tokgozoglu SL, Alikasifoglu M, Unsal, Atalar E, Aytemir K, Ozer N, et al. Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate. Heart 1999; 81(5): 518-22.
17. Golbahar J, Rezaian GR. Association of Hyperhomocysteinemia with Coronary Artery Disease in Southern Iran. IJMS 2004; 29(3): 116.
18. Hajimoradi B, Bahrami GR, Kiani A, Kazerani H, Moloudi A, Rai A, et al. Homocysteine level in patients with premature coronary artery disease. Hakim Research Journal 2007; 9(4): 31-6.
19. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274(13): 1049-57.
20. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24(4): 704-9.
21. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158(8): 862-7.
22. Wilcken DE, Wang XL, Wilcken B. Methylene tetrahydrofolate reductase (MTHFR) mutation, homocyst(e)ine, and coronary artery disease. Circulation 1997; 96(8): 2738-40.
23. Brattstrom L. Common mutation in the methylene tetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease. Circulation 1997; 96(10): 3805-7.
24. Donner MG, Klein GK, Mathes PB, Schwandt P, Richter WO. Plasma total homocysteine levels in patients with early-onset coronary heart disease and a low cardiovascular risk profile. Metabolism 1998; 47(3): 273-9.
25. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288(16): 2015-22.
26. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17(10): 1947-53.
27. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106(1): 9-19.
28. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338(15): 1042-50.
29. Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, Lennon L, et al. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart 1999; 82(4): 448-54.
30. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99(1): 178-82.
31. Brattstrom L, Israelsson B, Lindgarde F, Hultberg B. Higher total plasma homocysteine in vitamin B12 deficiency than in heterozygosity for homocystinuria due to cystathionine beta-synthase deficiency. Metabolism 1988; 37(2): 175-8.
32. Daly L, Robinson K, Tan KS, Graham IM. Hyperhomocysteinaemia: a metabolic risk factor for coronary heart disease determined by both genetic and environmental influences? Q J Med 1993; 86(10): 685-9.
33. Bailey LB, Gregory JF, III. Polymorphisms of methylene tetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr 1999; 129(5): 919-22.
34. Fletcher O, Kessling AM. MTHFR association with arteriosclerotic vascular disease? Hum Genet 1998; 103(1): 11-21.
35. Franco RF, Araujo AG, Guerreiro JF, Elion J, Zago MA. Analysis of the 677 C->T mutation of the methylene tetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost 1998; 79(1): 119-21.
36. Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylene tetrahydrofolate reductase mutation. Am J Hum Genet 1998; 62(5): 1258-60.
37. Ou T, Yamakawa-Kobayashi K, Arinami T, Amemiya H, Fujiwara H, Kawata K, et al. Methylene tetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. Atherosclerosis 1998; 137(1): 23-8.
38. Morita H, Kurihara H, Tsubaki S, Sugiyama T, Hamada C, Kurihara Y, et al. Methylene tetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol 1998; 18(9): 1465-9.
39. Izumi M, Iwai N, Ohmichi N, Nakamura Y, Shimoike H, Kinoshita M. Molecular variant of 5,10- methylenetetrahydrofolate reductase is a risk factor of ischemic heart disease in the Japanese population. Atherosclerosis 1996; 121(2): 293-4.
40. Kazemi MB, Eshraghian K, Omrani GR, Lankarani KB, Hosseini E. Homocysteine level and coronary artery disease. Angiology 2006; 57(1): 9-14.
41. Namazi MH, Motamedi MR, Safi M, Vakili H, Saadat H, Nazari N. Efficacy of folic acid therapy for prevention of in-stent restenosis: a randomized clinical trial. Arch Iran Med 2006; 9(2): 108-10.